Cargando…

Fingolimod Prevents Blood-Brain Barrier Disruption Induced by the Sera from Patients with Multiple Sclerosis

OBJECTIVE: Effect of fingolimod in multiple sclerosis (MS) is thought to involve the prevention of lymphocyte egress from lymphoid tissues, thereby reducing autoaggressive lymphocyte infiltration into the central nervous system across blood-brain barrier (BBB). However, brain microvascular endotheli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishihara, Hideaki, Shimizu, Fumitaka, Sano, Yasuteru, Takeshita, Yukio, Maeda, Toshihiko, Abe, Masaaki, Koga, Michiaki, Kanda, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361641/ https://www.ncbi.nlm.nih.gov/pubmed/25774903 http://dx.doi.org/10.1371/journal.pone.0121488

Ejemplares similares

Fingolimod promotes blood–nerve barrier properties in vitro
por: Nishihara, Hideaki, et al.
Publicado: (2018)

Sera from Remitting and Secondary Progressive Multiple Sclerosis Patients Disrupt the Blood-Brain Barrier
por: Shimizu, Fumitaka, et al.
Publicado: (2014)

Markedly Increased IP-10 Production by Blood-Brain Barrier in Neuromyelitis Optica
por: Shimizu, Fumitaka, et al.
Publicado: (2015)

Autocrine TNF-α Increases Penetration of Myelin-Associated Glycoprotein Antibodies Across the Blood-Nerve Barrier in Anti-MAG Neuropathy
por: Sato, Ryota, et al.
Publicado: (2023)

Severity and Patterns of Blood-Nerve Barrier Breakdown in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Correlations with Clinical Subtypes
por: Shimizu, Fumitaka, et al.
Publicado: (2014)

GRP 78 antibodies are associated with clinical phenotype in neuromyelitis optica
por: Shimizu, Fumitaka, et al.
Publicado: (2019)

Jo-1 Antibodies From Myositis Induce Complement-Dependent Cytotoxicity and TREM-1 Upregulation in Muscle Endothelial Cells
por: Honda, Masaya, et al.
Publicado: (2023)

GRP78 Antibodies Are Associated With Blood-Brain Barrier Breakdown in Anti–Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disorder
por: Shimizu, Fumitaka, et al.
Publicado: (2021)

Effects of neuromyelitis optica–IgG at the blood–brain barrier in vitro
por: Takeshita, Yukio, et al.
Publicado: (2016)

Advancing human induced pluripotent stem cell‐derived blood‐brain barrier models for studying immune cell interactions
por: Nishihara, Hideaki, et al.
Publicado: (2020)

Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
por: Spampinato, Simona F., et al.
Publicado: (2015)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD
por: Takeshita, Yukio, et al.
Publicado: (2021)

Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod
por: Fukai, Ryoko, et al.
Publicado: (2019)

Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis
por: Sato, Kazunori, et al.
Publicado: (2018)

Antineutrophil cytoplasmic antibody-associated vasculitis with predominant truncal muscle weakness: a retrospective case series
por: Nemoto, Joe, et al.
Publicado: (2023)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Contribution of brain pericytes in blood–brain barrier formation and maintenance: a transcriptomic study of cocultured human endothelial cells derived from hematopoietic stem cells
por: Heymans, Marjolein, et al.
Publicado: (2020)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Development of a human in vitro blood–brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance
por: Deligne, Clémence, et al.
Publicado: (2020)

A perfused human blood–brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport
por: Wevers, Nienke R., et al.
Publicado: (2018)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis
por: Ohtani, Ryohei, et al.
Publicado: (2018)

Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis
por: Khan, Asma A, et al.
Publicado: (2023)

Blood–Nerve Barrier (BNB) Pathology in Diabetic Peripheral Neuropathy and In Vitro Human BNB Model
por: Takeshita, Yukio, et al.
Publicado: (2020)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011)

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
por: Marriott, James J.
Publicado: (2011)

Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients
por: Farrokhi, Mehrdad, et al.
Publicado: (2015)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2017)

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
por: Bascuñana, Pablo, et al.
Publicado: (2020)

Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod
por: Abrahamowicz, Aleksandra A., et al.
Publicado: (2021)

Modulation of Tregs and iNKT by Fingolimod in Multiple Sclerosis Patients
por: Ferraro, Diana, et al.
Publicado: (2021)

Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis
por: Vaheb, Saeed, et al.
Publicado: (2023)

Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod
por: Murgia, Federica, et al.
Publicado: (2023)

Immuno-metabolic impact of the multiple sclerosis patients’ sera on endothelial cells of the blood-brain barrier
por: Sheikh, M. H., et al.
Publicado: (2020)

Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
por: Sharma, Sushil, et al.
Publicado: (2011)

Early Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis
por: Liu, Lei, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2p1sps0vivtqtokshfgjdb19rv